MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment
MEK2 是接受替莫唑胺治疗的胶质瘤患者的预后标志物和潜在的化学增敏靶点
期刊:Cellular & Molecular Immunology
影响因子:21.8
doi:10.1038/cmi.2015.46
Hua He, Maojin Yao, Wenhao Zhang, Bangbao Tao, Feili Liu, Shu Li, Yan Dong, Chenran Zhang, Yicheng Meng, Yuxin Li, Guohan Hu, Chun Luo, Hui Zong, Yicheng Lu